NCT00802594View on ClinicalTrials.gov

A Trial of DB289 for the Treatment of Stage I African Trypanosomiasis

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 31, 2001

Primary Completion Date

August 31, 2002

Study Completion Date

November 30, 2004

Conditions
Trypanosomiasis, African
Interventions
DRUG

DB289

A single 100 mg DB289 capsule will be taken by mouth twice a day, morning and evening. Drug is to be taken with a glass of water within 15 minutes of the completion of meal.

Trial Locations (2)

CP 2657-C

Laboratory of Reference and Investigation, Viana, ICCT, Bairro Ingombota

Unknown

Programme National de Lutte contre la Trypanosomiase, Kinshasa

Sponsors
All Listed Sponsors
collaborator

Bill and Melinda Gates Foundation

OTHER

lead

Immtech Pharmaceuticals, Inc

INDUSTRY